FDA Approves ImmunityBio's Anktiva To Treat Adults With Bacillus Calmette-Guerin Unresponsive Non-Muscle Invasive Bladder Cancer

The FDA has approved ImmunityBio's Anktiva for the treatment of adults with Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer. This approval expands the therapeutic options available for patients who do not respond to standard BCG therapy. The stock ticker for ImmunityBio is IBRX.